Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension

ClinicalTrials.gov ID: NCT03926793

Public ClinicalTrials.gov record NCT03926793. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 8:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b, Randomized, Subject- and Investigator-Blinded, Placebo-Controlled, Multi-Center Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Biomarkers of Inhaled GB002 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension (PAH)

Study identification

NCT ID
NCT03926793
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Enrollment
8 participants

Conditions and interventions

Interventions

  • GB002 Drug
  • Placebo Drug
  • Generic Dry Powder Inhaler Device

Drug · Device

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 3, 2020
Primary completion
May 4, 2021
Completion
May 4, 2021
Last update posted
Aug 31, 2021

2020 – 2021

United States locations

U.S. sites
12
U.S. states
11
U.S. cities
12
Facility City State ZIP Site status
UCSD Medical Center La Jolla California 92037
University of California Davis Medical Center Sacramento California 95817
University of Colorado Hospital Aurora Colorado 80045
Yale New Haven Hospital New Haven Connecticut 06510
Mayo Clinic Florida Jacksonville Florida 32224
Norton Pulmonary Specialists Louisville Kentucky 40202
Brigham and Women's Hospital Boston Massachusetts 02115
Mayo Clinic Rochester Minnesota 55905
Duke Early Phase Research Durham North Carolina 27710
Cleveland Clinic Foundation Cleveland Ohio 44195
University of Pittsburgh Medical Center Montefiore University Hospital Pittsburgh Pennsylvania 15213
VitaLink Research - Anderson Anderson South Carolina 29621

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03926793, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 31, 2021 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03926793 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →